Dr Reddy's To Market Amgen Therapies In India
This article was originally published in Scrip
Executive Summary
Dr Reddy's Laboratories is to market and distribute three Amgen therapies, including the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor Repatha (evolocumab) on the Indian market.